# A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease

> **NCT03119662** · PHASE4 · TERMINATED · sponsor: **GE Healthcare** · enrollment: 4 (actual)

## Conditions studied

- Chronic Kidney Diseases

## Interventions

- **DRUG:** Visipaque
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03119662
- **Lead sponsor:** GE Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-08
- **Primary completion:** 2018-09-13
- **Final completion:** 2018-10-19
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** The trial was discontinued due to a lower than anticipated recruitment rate. The decision has not been made due to any safety reasons.
- **Last updated:** 2019-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03119662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03119662, "A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03119662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*